Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 94.94
Day High 95.55
Open:95.14
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

U.S. FDA Approves INREBIC(R) (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
- BusinessWire - Fri Aug 16, 9:30AM CDT
BusinessWire - CMTX
Fri Aug 16, 9:30AM CDT
Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC(R) (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.(1)
Celgene Corp Rises 1.12% on Heavy Volume: Watch For Potential Pullback
- Comtex SmarTrend(R) - Thu Aug 8, 12:33PM CDT
Comtex SmarTrend(R) - CMTX
Thu Aug 8, 12:33PM CDT
Celgene Corp (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $92.70 to a high of $95.07. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $94.30 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Celgene Reports Second Quarter 2019 Operating and Financial Results
BusinessWire - Tue Jul 30, 6:30AM CDT
BusinessWire - CMTX
Tue Jul 30, 6:30AM CDT
Celgene Corporation (NASDAQ: CELG) reported second quarter 2019 total revenue of $4,400 million, a 15 percent increase compared to $3,814 million in the second quarter of 2018.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 89.08 +7.20% increase
on 07/23/19
Period Open:90.20
Price movement based on the high, low and last over the given period.
95.59 -0.10% decrease
on 08/09/19
+5.30 (+5.87%) increase
since 07/19/19
3-Month 89.08 +7.20% increase
on 07/23/19
Period Open:94.83
Price movement based on the high, low and last over the given period.
98.97 -3.51% decrease
on 06/21/19
+0.67 (+0.70%) increase
since 05/20/19
52-Week 58.59 +62.99% increase
on 12/26/18
Period Open:90.88
Price movement based on the high, low and last over the given period.
98.97 -3.51% decrease
on 06/21/19
+4.62 (+5.08%) increase
since 08/20/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).